Genentech to use Vysis' HER-2 test
Genentech will use Vysis' (genetic testing; a division of BP Amoco) PathVysion fluorescent in situ hybridization (FISH) DNA test for the HER-2 gene to assess patients taking Herceptin (trastuzumab), and also in future clinical trials of the drug.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
Drug Discovery Tools
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.